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Methicillin-resistant Staphylococcus aureus (MRSA) stand out as one of the main agents causing 
nosocomial and community infections. This retrospective study aimed to analyze the MRSA predominance 
in a university hospital in the south of Brazil and it was carried out for five years (from 2007 to 2011). 
616 MRSA (33,3% of the total) were isolated and an important reduction in the MRSA predominance 
was observed along the study. Although it was registered a reduction in the MRSA predominance, 
male adult patients (41-70 years old), who were in the Medical Clinic and Adult ICU, had the highest 
infection rates and concerning MRSA isolates rates, these were higher in blood and tracheal aspirates. 
In conclusion, studies of this type are becoming relevant to recognize pathogens like MRSA and to 
determine its predominance.
Uniterms: Staphylococcus aureus/methicillin-resistant. Resistant pathogens. Methicillin. University 
hospitals/infection.
Staphylococcus aureus resistentes à meticilina (MRSA) destacam-se mundialmente como um dos mais 
frequentes patógenos nosocomiais e comunitários. Este estudo retrospectivo teve por objetivo analisar 
a prevalência de MRSA em um hospital universitário no sul do Brasil. Durante cinco anos (2007 a 
2011), 616 MRSA (33,3% do total de S. aureus) foram isolados, sendo que sua frequência de isolamento 
apresentou considerável redução no decorrer do estudo. Nossos resultados demonstraram que as maiores 
taxas de isolamento dos MRSA ocorreram em amostras de sangue e secreção traqueal. As infecções 
prevaleceram em pacientes adultos (41 a 70 anos), do sexo masculino, internados na Clínica Médica e 
UTI adulto. Estudos como este se tornam importantes para o reconhecimento de patógenos resistentes, 
como o MRSA, e para a determinação da sua prevalência.
Unitermos: Staphylococcus aureus/resistentes à meticilina. Patógenos resistentes. Meticilina. Hospital 
universitário/infecções.
INTRODUCTION
Staphylococcus aureus is worldly known as one 
of main responsible agents, which cause a wide number 
of infections including septicemia, pneumonia, skin and 
soft tissues infections (Dong et al., 2013). It is considered 
an important etiological agent in nosocomial infections 
as well as in ones acquired in the community (François 
et al., 2007). The occurrence of methicillin-resistant 
Staphylococcus aureus strains has become a great 
challenge due to its prevalence in hospital environment 
infections as well as in community infections (Boucher, 
Corey, 2008).
MRSA was firstly reported in hospitals (healthcare-
associated MRSA - HA-MRSA) in the United Kingdom 
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in 1961 and after that, it spread to many other health 
institutions all over the world (Jevons, 1961; Deurenberg 
et al., 2007). Regarding hospital environment, the MRSA 
colonization or infection was associated to risk factors like 
recent surgery, in hospital patients, chronic diseases and 
presence of a catheter among others.
After two decades, the first MRSA cases acquired 
in the community were reported (CA-MRSA) (Saravolatz 
et al., 1982; Saravolatz, Pohlod, Arking, 1982) and since 
1990 an increase in the infection occurrence caused 
by CA-MRSA has been reported in many countries 
(Deurenberg et al., 2007; Skov et al., 2012). The 
emergence of infections caused by this microorganism, 
when risk factors are absent, marked the beginning of a 
public health problem (Sdougkos et al., 2008).
In Europe, the MRSA are well known among the 
multiresistant bacteria, which are the most involved in 
infections related to health assistance (European Centre 
for Disease Prevention and Control, European Medicines 
Agency, 2009). Considering United States and Latin 
America, this microorganism constitutes the main bacterial 
agent involved in nosocomial infections also presenting a 
growing involvement in the prevalence of infections in the 
community (Wallin, Hern, Frazee, 2008; Guzmán-Blanco 
et al., 2009). 
This study aims to determine the MRSA prevalence 
in different clinical samples making use of a retrospective 
analysis of bacteriological tests carried out in a tertiary 
university hospital.
MATERIAL AND METHODS
This retrospective study was carried out through a 
research in the Microbiology Laboratory database of the 
University Hospital of Santa Maria (HUSM), which has 
37 beds for intensive care and 291 beds for admission, in 
the city of Santa Maria, south of Brazil. This hospital is 
a tertiary one, which provides medical assistance for 30 
cities from the central region of Rio Grande do Sul (RS) 
state.
The data of all cultures where S. aureus growing was 
observed from January 1st, 2007 to December 31st, 2011 
were analyzed.
Inclusion criteria of MRSA samples
It was considered as MRSA all S. aureus isolates, 
which presented resistance to oxacillin and/or cefoxitin. 
Such consideration was carried out through conventional 
phenotypic methodology, through disk diffusion technique 
(Kirby-Bauer), and the isolates were confirmed through 
automated phenotypic methodology (MicroScan® – 
Siemens), according to the standards established by 
the Clinical and Laboratory Standards Institute (CLSI) 
prevailing in each year.
In this study, only the first bacterial sample of S. 
aureus isolates from each patient was used.
Ethics Committee
This study was submitted to the Reseach Ethics 
Committee (CEP) of the Federal University of Santa Maria 
and it was approved under the number 0117.0.243.000-08.
Statistical Analysis
The experimental data were evaluated through 
Chi-Square test where a value of p<0,05 was considered 
statistically significant.
RESULTS
This study was carried out for five years (2007 
to 2011). During this time 1.852 samples of S. aureus 
were isolated and 616 (33.3%) were oxacillin-resistant 
(MRSA). The MRSA prevalence as well as the oxacillin-
sensitive S. aureus (MSSA) according to each year can 
be observed on Table I. The annual MRSA prevalence is 
shown on Figure 1.
The distribution of MRSA isolates was predominantly 
in male patients (Figure 2). 
Regarding age groups during all study period, it was 
registered a bigger predominance among patients with 
ages between 41-70 years (258/594) (Table II). The age 
of the patient was not registered in 22 cases.
The hospital units, which registered bigger 
predominance of MRSA isolates, were arranged in a 
descending order, as it can be seen on Table III. The 
order is: Medical Clinic (99/608), Adult Intensive Care 
(ICU) (92/608), Ambulatory (79/608), Adult Emergency 
(77/608) and Clinical Surgery (76/608). It was found 8 
clinical records without the register concerning which 
hospital unit the patient was.
The clinical materials where MRSA isolates had 
predominance were: blood (104/16.9%), tracheal aspirates 
(102/16.5%), urine (64/10.4%), sputum (54/8.7%), 
secretion of surgical wound (50/8.1%) and secretion of 
lower limb (48/7.8%). 195 isolates (31.6%) came from 
other clinical samples as: catheter tip, tracheal aspirates, 
bronchoalveolar lavage, cerebrospinal fluid, among others. 
Figure 3 displays the biological materials, which had more 
prevalence of MRSA isolates.
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TABLE I – Prevalence of MRSA and MSSA isolates at HUSM, from 2007 to 2011
MRSA MSSA
Total (%) Total of positive 
cultures at LACn (total) % n (total) %
2007 181 43,4 236 56,6 417 (100) 3.642
2008 149 33,9 290 66,1 439 (100) 4.320
2009 104 30,4 238 69,6 342 (100) 3.993
2010 95 28,1 243 71,9 338 (100) 3.958
2011 87 27,5 229 72,5 316 (100) 4.864
Total 616 1.236 1.852 20.777
LAC = Laboratory of Clinical Analysis.
FIGURE 1 – Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus 
(MSSA) isolates at HUSM from 2007 to 2011. 
FIGURE 2 – Distribution of patients with infections caused by MRSA at HUSM from 2007 to 2011 according to gender.
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DISCUSSION
MRSA are the main responsible agents, which 
cause nosocomial infections all over the world (Japoni 
et al., 2010). In Brazil, the MRSA prevalence varies 
according to the regions and to the clinical material 
from which this important pathogen is isolated, 
presenting rates between 44% to 56% (Ferreira et al., 
2009; Carvalho, Mamizuka, Gontijo Filho, 2010). In the 
European Community, the MRSA reach different rates 
among its countries having less than 1% to more than 
24% (Dulon et al., 2011; European Centre for Disease 
Prevention and Control, European Medicines Agency, 
2009), however, in the USA these rates can reach 38.2% 
(Jarvis, Jarvis, Chinn, 2012).
During the five years of study, the MRSA prevalence 
TABLE II – Age groups of MRSA isolates (2007 to 2011) at HUSM
Age 2007 2008 2009 2010 2011 Total
≤ 10 years old 21 15 14 10 14 74
11 – 40 years old 49 36 39 18 25 167
41 – 70 years old 67 70 29 48 44 258
≥ 71 years old 35 24 19 13 4 95
Total 172 145 101 89 87 594
TABLE III – MRSA isolates according to Hospital Units, in the years of 2007 to2011
Hospital Unit 2007 2008 2009 2010 2011 Total (%)
Medical Clinic 27 32 15 15 10 99 (16.28)
Adult ICU* 31 23 15 14 9 92 (15.13)
Ambulatory 22 15 16 12 14 79 (13.00)
Adult Emergency 25 15 12 16 9 77 (12.67)
Clinical Surgery 27 19 10 11 9 76 (12.50)
UTI RN** 10 4 4 5 6 29 (4.77)
Nephrology 6 9 3 3 2 23 (3.78)
ICU Pediatric 6 7 3 1 3 20 (3.29)
Obstetric Center 4 2 4 2 4 16 (2.63)
Oncology Unit 4 5 4 - 3 16 (2.63)
Obstetric and Gynecologic Unit 1 1 7 2 3 14 (2.30)
Surgery Unit 4 4 1 1 3 13 (2.14)
CTCriaC*** 2 2 1 2 4 11 (1.81)
Recovery Room 2 3 3 2 1 11 (1.81)
Pediatric Unit 1 3 - 2 3 9 (1.48)
Pediatric Emergency 2 2 1 1 2 8 (1.31)
Intensive Coronary Care Unit 2 1 - 1 - 4 (0.66)
CTMO+ - 1 - 1 1 3 (0.50)
Hemato-Oncology 1 - - 1 1 3 (0.50)
SID++ 1 - 1 - - 2 (0.33)
Psychiatric Unit - - 1 1 - 2 (0.33)
Radiotherapy 1 - - - - 1 (0.16)
Total 179 148 101 93 87 608 (100)
ICU* – Intensive Care Unit; UTI RN** - Intensive Care Unit for Newborns; CTCriaC*** – Center for Treatment of Infant Cancer; 
CTMO+ – Center for Bone Marrow Transplant; SID++ – Home Care Service
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FIGURE 3 – Distribution of clinical samples with more prevalence of MRSA isolates at HUSM from 2007 to 2011.
average rate at HUSM was 33.3% and similar rate to the 
one found in this work with an index equal or higher than 
25% is found in data from the European Antimicrobial 
Resistance Surveillance System (2009), in countries like 
Greece, Italy, Bulgary, Turkey and Spain.
I t  was  a lso  found a  s igni f icant  reduct ion 
(approximately 40%) in the MRSA prevalence rates 
decreasing its percentage of 43.4% in 2007 to 27.5%, in 
2011 (p<0.05). Such reduction at HUSM was due possibly 
to the work of the Committee on Hospital Infection 
Control, which since 2006 has established actions as 
discontinuation of antibiotic therapy and professional 
training and a more rigid antimicrobial distribution aiming 
at reducing these rates. Programs of prevention and control 
of the MRSA carried out in some hospitals in the European 
Community have become priority to public health and 
have reached satisfactory results due to the reduction in 
the MRSA infection rates in these countries (Köck et al., 
2010).
When genders are compared, it was observed that a 
small prevalence of MRSA infections happen with men. 
Such data was registered in all years of the study period 
(Figure 2) having an average rate of 60.6%. Such results 
are similar to the ones found by Mahmood et al. (2010) 
in Pakistan between 2005 and 2009 and by Jarvis, Jarvis, 
Chinn (2012) in the USA. Both teams verified that 58% 
and 52.2% of patients hospitalized with MRSA were men 
respectively.
Although the majority of the infection cases 
happen with 41 to 70 year-old adults (Table II), in 2009 
was registered a higher number of MRSA isolates in 
adolescents and young adults (11-40 year-old patients). 
The highest infection predominance in adults and 
mainly with elderly people is due to their vulnerability 
because they are more frequently exposed to excessive 
manipulation and invasive procedures (Souza, Figueiredo, 
2008). Patients infected by MRSA belonging to the same 
age group were also reported in other studies (Mahmood 
et al., 2010; Souza, Figueiredo, 2008). 
According to the hospital unit, the Medical Clinic 
followed by the Adult ICU were the ones which presented 
the highest index, representing respectively 16.3% and 
15.1% of the total MRSA isolates. The Ambulatory 
(13.0%), Adult Emergency (12.7%) and Clinical Surgery 
(12.5%) also reached relevant MRSA isolates rates at 
HUSM. Other authors in Brazil as well as in the USA 
also report higher MRSA prevalence in ICUs, as it was 
reported in our study (Souza, Figueiredo, 2008; Jarvis, 
Jarvis, Chinn, 2012). This data is justified by the fact 
that patients in ICUs are frequently submitted to medical 
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and therapeutic interventions, it is applied a big number 
of invasive medical devices and besides it is employed 
multiple therapies that can trigger the development of a 
MRSA infection (Verdier et al., 2006). Furthermore, data 
from the National Nosocomial Infections Surveillance 
of the Center for Disease Control and Prevention (CDC) 
in the USA show that since 1999, the MRSA prevalence 
rates are beyond 50% among patients in ICUs (Moura et 
al., 2007).
The clinical materials, which presented the 
biggest number of MRSA isolates were blood, tracheal 
aspirates, urine, sputum, secretion of surgical wound 
and secretion of lower limb. In the USA and in some 
European countries, the incidence of bacteremia caused 
by MRSA has increased in the last years (Shorr, Lodise, 
2006). According to a study carried out in Iran, in 2007, 
Japoni et al. (2010) reported a bigger number of MRSA 
isolates in blood, sputum and wound samples while 
Mahmood et al. (2010) reported a bigger incidence in 
sputum samples. In Brazil, Souza, Figueiredo (2008) in 
2008, at the Regional University Hospital of Maringá 
found a bigger incidence of MRSA isolates in catheter 
tips and tracheal secretion.
CONCLUSION
This research found out that the MRSA prevalence 
rate showed substantial reduction from 2007 to 2011 
and such reduction is possibly related to the collective 
construction of a MRSA prevention and control “bundle” 
guided by the practical criteria of the Committee on 
Hospital Infection Control at HUSM.
Infections caused by MRSA constitute an important 
world challenge in the public health system knowledge 
concerning MRSA prevalence rates at the University 
Hospital of Santa Maria together with the effective actions, 
concerning MRSA infections, registered by the Committee 
on Hospital Infection Control has a direct impact on 
the health system of our country in terms of morbidity, 
mortality and financial costs.
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